Article

Symposium tackles difficult issues of glaucoma

Cardiovascular medicine has provided a road map that ophthalmology can follow in risk assessment.

Related Videos
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Related Content
ASU researchers tap AI to help people see more clearly
October 7th 2024

ASU researchers tap AI to help people see more clearly

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

A clear path ahead
August 13th 2024

A clear path ahead

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Clinical trial recruitment and AI: Easing the burden of GA studies
July 22nd 2024

Clinical trial recruitment and AI: Easing the burden of GA studies

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO
July 5th 2024

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

© 2024 MJH Life Sciences

All rights reserved.